Krebs Biochemicals & Industries Beheer

Beheer criteriumcontroles 2/4

De CEO Krebs Biochemicals & Industries is Jitendra Shah, benoemd in Aug2023, heeft een ambtstermijn van 1.25 jaar. bezit rechtstreeks 0% van de aandelen van het bedrijf, ter waarde ₹ 8.20K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 9.5 jaar.

Belangrijke informatie

Jitendra Shah

Algemeen directeur

₹1.9m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.3yrs
Eigendom CEO	0.0005%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	9.5yrs

Recente managementupdates

Recent updates

CEO

Jitendra Shah (56 yo)

1.3yrs

Tenure

₹1,945,000

Compensatie

Mr. Jitendra Rameshchandra Shah serves as an Executive Director of Krebs Biochemicals & Industries Limited since August 10, 2023 and served its Additional Non-Executive Director of Krebs Biochemicals & Ind...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jitendra Shah	MD, CEO & Director	1.3yrs	₹1.95m	0.00046% ₹ 8.2k
Ritesh Jain	Chief Financial Officer	1.8yrs	geen gegevens	geen gegevens
Rakesh Kalbate	Company Secretary & Compliance Officer	less than a year	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van KREBSBIO wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jitendra Shah	MD, CEO & Director	3yrs	₹1.95m	0.00046% ₹ 8.2k
Ravi Tagore	Non-Executive Chairman	32.1yrs	₹70.00k	0.11% ₹ 1.9m
Gundapaneni Venkata Prasad	Independent Non-Executive Director	20.2yrs	₹90.00k	0.66% ₹ 11.8m
Avinash Ravi	Non-Executive Director	15.8yrs	₹55.00k	9.93% ₹ 177.0m
Pabitra Kumar Bhattacharya	Non-Executive Director	3.3yrs	₹1.10m	0.000020% ₹ 356.7
Satish Khivsara	Independent Non-Executive Director	9.3yrs	₹110.00k	0.0049% ₹ 86.9k
Malati Tangirala	Independent Non-Executive Director	9.8yrs	₹90.00k	geen gegevens
Raj Kamal Verma	Independent Non-Executive Director	8.8yrs	₹45.00k	0.00097% ₹ 17.3k

9.5yrs

Gemiddelde duur

71yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van KREBSBIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.5 jaar).

Krebs Biochemicals & Industries Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Krebs Biochemicals & Industries Limited, Annual General Meeting, Sep 27, 2024

Insufficient new directors

Krebs Biochemicals & Industries Limited Appoints Keyur Doshi as Company Secretary, Compliance Officer

Krebs Biochemicals & Industries Limited Announces Resignation of Rohit Taparia as Company Secretary and Compliance Officer

Krebs Biochemicals & Industries Limited, Annual General Meeting, Sep 27, 2023

Krebs Biochemicals & Industries Limited Approves CFO Changes

Recent updates

Second quarter 2025 earnings released: ₹2.67 loss per share (vs ₹1.66 loss in 2Q 2024)

Krebs Biochemicals & Industries Limited to Report Q2, 2025 Results on Nov 11, 2024

Krebs Biochemicals & Industries Limited, Annual General Meeting, Sep 27, 2024

First quarter 2025 earnings released: ₹2.40 loss per share (vs ₹2.47 loss in 1Q 2024)

Insufficient new directors

Krebs Biochemicals & Industries Limited to Report Q1, 2025 Results on Aug 07, 2024

Full year 2024 earnings released: ₹9.16 loss per share (vs ₹11.45 loss in FY 2023)

Krebs Biochemicals & Industries Limited to Report Q4, 2024 Results on May 21, 2024

Third quarter 2024 earnings released: ₹2.31 loss per share (vs ₹2.58 loss in 3Q 2023)

Krebs Biochemicals & Industries Limited to Report Q3, 2024 Results on Feb 12, 2024

Krebs Biochemicals & Industries Limited Appoints Keyur Doshi as Company Secretary, Compliance Officer

Second quarter 2024 earnings released: ₹1.66 loss per share (vs ₹1.88 loss in 2Q 2023)

New minor risk - Share price stability

Krebs Biochemicals & Industries Limited Announces Resignation of Rohit Taparia as Company Secretary and Compliance Officer

Krebs Biochemicals & Industries Limited to Report Q2, 2024 Results on Nov 08, 2023

Krebs Biochemicals & Industries Limited, Annual General Meeting, Sep 27, 2023

First quarter 2024 earnings released: ₹2.47 loss per share (vs ₹3.77 loss in 1Q 2023)

Krebs Biochemicals & Industries Limited to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings released: ₹11.30 loss per share (vs ₹20.65 loss in FY 2022)

Krebs Biochemicals & Industries Limited to Report Q4, 2023 Results on May 24, 2023

Third quarter 2023 earnings released: ₹2.58 loss per share (vs ₹6.00 loss in 3Q 2022)

Krebs Biochemicals & Industries Limited Approves CFO Changes

Krebs Biochemicals & Industries Limited to Report Q3, 2023 Results on Feb 03, 2023

Second quarter 2023 earnings released: ₹1.88 loss per share (vs ₹5.05 loss in 2Q 2022)

Second quarter 2023 earnings released: ₹1.88 loss per share (vs ₹5.05 loss in 2Q 2022)

Krebs Biochemicals & Industries Limited to Report Q2, 2023 Results on Nov 10, 2022

Krebs Biochemicals & Industries Limited, Annual General Meeting, Sep 30, 2022

First quarter 2023 earnings released: ₹3.77 loss per share (vs ₹4.37 loss in 1Q 2022)

Taruni Banda Resigns as Company Secretary and Compliance Officer of Krebs Biochemicals & Industries Limited, Effective from August 6, 2022

Krebs Biochemicals & Industries Limited to Report Q1, 2023 Results on Aug 01, 2022

Full year 2022 earnings released: ₹21.21 loss per share (vs ₹14.45 loss in FY 2021)

Krebs Biochemicals & Industries Limited to Report Q4, 2022 Results on May 23, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: ₹5.05 loss per share (vs ₹3.26 loss in 2Q 2021)

Non-Executive Director Manish Jain has left the company

First quarter 2022 earnings released: ₹4.37 loss per share (vs ₹3.43 loss in 1Q 2021)

Full year 2021 earnings released: ₹14.53 loss per share (vs ₹16.04 loss in FY 2020)

Third quarter 2021 earnings released: ₹4.21 loss per share (vs ₹4.60 loss in 3Q 2020)

Krebs Biochemicals & Industries Limited to Report Q3, 2021 Results on Jan 30, 2021

New 90-day high: ₹138

New 90-day high: ₹94.40

Krebs Biochemicals & Industries Limited to Report Q2, 2021 Results on Nov 05, 2020

Krebs Biochemicals & Industries Limited to Report Q1, 2021 Results on Aug 07, 2020

Earnings released

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd